Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

NCT01125046 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acoustic Schwannoma
Adult Anaplastic Meningioma
Adult Ependymoma
Adult Grade I Meningioma
Adult Grade II Meningioma
Adult Meningeal Hemangiopericytoma
Adult Papillary Meningioma
Neurofibromatosis Type 1
Neurofibromatosis Type 2
Recurrent Adult Brain Tumor

Interventions

BIOLOGICAL: bevacizumab

Sponsor

Northwestern University